UTHR CFO exercises options, sells 10k shares
United Therapeutics CFO and Treasurer James Edgemond exercised stock options for 10,000 shares of common stock at an exercise price of $135.42 per share.
Rhea-AI Filing Summary
United Therapeutics CFO and Treasurer James Edgemond exercised stock options for 10,000 shares of common stock at an exercise price of $135.42 per share. On the same date, he sold 10,000 shares of common stock in multiple open-market trades at prices generally in the mid-$550s. These transactions were carried out under a pre-arranged Rule 10b5-1 trading plan entered into on October 31, 2025. Following the transactions, he directly holds 18,876 shares of common stock and 112,500 stock options.
Positive
- None.
Negative
- None.
Insider Trade Summary 10b5-1
Exercise and Sale: 10,000 shares ($4.23M approx. pre-tax spread)
Exercise and Sale
15 txns
Insider
EDGEMOND JAMES
Role
CFO AND TREASURER
Sold
10,000 shs ($5.58M)
Approx. gross sale proceeds
$5.58M
Approx. exercise cost
$1.35M
Approx. pre-tax spread
$4.23M
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Option | 10,000 | $0.00 | $0.00 |
| Exercise | Common Stock | 10,000 | $135.42 | $1.35M |
| Sale | Common Stock | 120 | $552.7801 | $66K |
| Sale | Common Stock | 437 | $553.9678 | $242K |
| Sale | Common Stock | 1,158 | $555.2131 | $643K |
| Sale | Common Stock | 1,205 | $556.0597 | $670K |
| Sale | Common Stock | 1,840 | $557.1897 | $1.03M |
| Sale | Common Stock | 1,679 | $558.3137 | $937K |
| Sale | Common Stock | 860 | $559.4673 | $481K |
| Sale | Common Stock | 616 | $560.1759 | $345K |
| Sale | Common Stock | 645 | $561.5572 | $362K |
| Sale | Common Stock | 619 | $562.7544 | $348K |
| Sale | Common Stock | 539 | $563.47 | $304K |
| Sale | Common Stock | 82 | $564.4276 | $46K |
| Sale | Common Stock | 200 | $566.01 | $113K |
Holdings After Transaction:
Stock Option — 112,500 contracts (Direct);
Common Stock — 18,876 shares (Direct)
Footnotes (14)
- F1. This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on October 31, 2025.
- F10. This transaction was executed in multiple trades at prices ranging from $561.12 to $562.02. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F11. This transaction was executed in multiple trades at prices ranging from $562.20 to $563.16. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F12. This transaction was executed in multiple trades at prices ranging from $563.20 to $563.96. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F13. This transaction was executed in multiple trades at prices ranging from $564.23 to $564.635. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F14. This transaction was executed in multiple trades at prices ranging from $565.99 to $566.04. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F2. This transaction was executed in multiple trades at prices ranging from $552.38 to $553.00. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F3. This transaction was executed in multiple trades at prices ranging from $553.61 to $554.55. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F4. This transaction was executed in multiple trades at prices ranging from $554.61 to $555.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F5. This transaction was executed in multiple trades at prices ranging from $555.63 to $556.60. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F6. This transaction was executed in multiple trades at prices ranging from $556.71 to $557.68. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F7. This transaction was executed in multiple trades at prices ranging from $557.79 to $558.78. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F8. This transaction was executed in multiple trades at prices ranging from $558.825 to $559.82. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- F9. This transaction was executed in multiple trades at prices ranging from $559.83 to $560.69. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Key Figures
Options exercised: 10,000 shares
Exercise price: $135.42/share
Shares sold: 10,000 shares
+5 more
8 metrics
Options exercised
10,000 shares
Stock option exercise into common stock on 2026-04-06
Exercise price
$135.42/share
Stock option exercise price for 10,000 shares
Shares sold
10,000 shares
Total United Therapeutics common shares sold in open market
Sale price range (low)
$552.78/share
Lowest reported weighted-average sale price in the transactions
Sale price range (high)
$566.01/share
Highest reported weighted-average sale price in the transactions
Shares held after
18,876 shares
Direct United Therapeutics common stock holdings post-transaction
Options held after
112,500 options
Total stock options held following the reported exercise
10b5-1 plan date
October 31, 2025
Date CFO entered the Rule 10b5-1 trading plan
Key Terms
Rule 10b5-1 trading plan, Stock Option, open-market sale, Exercise or conversion of derivative security, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"This exercise of stock options and subsequent sale of shares was pursuant to a Rule 10b5-1 trading plan..."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Stock Option financial
""security_title": "Stock Option""
A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.
open-market sale financial
""transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Exercise or conversion of derivative security financial
""transaction_code_description": "Exercise or conversion of derivative security""
weighted average price financial
"The price reported above reflects the weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did United Therapeutics (UTHR) CFO James Edgemond do in this Form 4?
CFO James Edgemond exercised options for 10,000 United Therapeutics shares at $135.42 and sold 10,000 shares in multiple open-market trades around the mid-$550s. The filing also updates his remaining direct share and option holdings.
What stock options did the United Therapeutics (UTHR) CFO exercise?
He exercised stock options covering 10,000 United Therapeutics common shares at an exercise price of $135.42 per share. These options had an original exercise date of March 15, 2023 and an expiration date of March 15, 2027.
Were the United Therapeutics (UTHR) CFO’s trades pre-planned under Rule 10b5-1?
Yes. A footnote states the option exercise and subsequent share sales were executed under a Rule 10b5-1 trading plan that the reporting person entered into on October 31, 2025, indicating the trades were pre-scheduled rather than opportunistic.
What does an open-market sale in a United Therapeutics (UTHR) Form 4 mean?
An open-market sale means shares were sold through standard market trading, not via a private agreement. In this case, the CFO’s United Therapeutics sales occurred in multiple trades within specified price ranges, with weighted average prices disclosed for each transaction.
AI-generated analysis. How Rhea-AI works. Not financial advice.
